A prognostic score for advanced Hodgkin's disease

New England Journal of Medicine

Volumn 339, Issue 21, 1998, Pages 1506-1514

  Hasenclever, Dirk ^a   Diehl, Volker ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; ANALYSIS OF VARIANCE; DISEASE PROGRESSION; FEMALE; HODGKIN DISEASE; HUMANS; LEUKOCYTE COUNT; LIFE TABLES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SURVIVAL RATE;

EID: 0032548107     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199811193392104     Document Type: Article

References (66)

1. Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986;4:1295-306.
2. Bonadonna G, Santoro A, Gianni AM, et al. Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience. Ann Oncol 1991;2:Suppl 1:9-16.
3. Henry-Amar M, Aeppli DM, Anderson J, et al. Workshop statistical report. In: Somers R, Henry-Amar M, Meerwaldt JH, Carde P, eds. Colloque INSERM. Vol. 196. London: John Libbey Eurotext, 1990:169-418.
4. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-84.
5. Hasenclever D, Loeffler M, Diehl V. Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease: German Hodgkin's Lymphoma Study Group. Ann Oncol 1996;7:Suppl 4:95-8.
6. Diehl V, Loeffler M, Pfreundschuh M, et al. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. Ann Oncol 1995;6:901-10.
7. Bjorkholm M, Axdorph U, Grimfors G, et al. Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease: a prospective randomized trial. Ann Oncol 1995;6:895-9.
8. Gisselbrecht C, Fermé C. Prognostic factors in advanced Hodgkin's disease: problems and pitfalls: towards an international prognostic index. Leuk Lymphoma 1995;15:Suppl 1:23-4.
9. Straus DJ. High-risk Hodgkin's disease prognostic factors. Leuk Lymphoma 1995;15:Suppl 1:41-2.
10. Carde P. Should poor risk patients with Hodgkin's disease be sorted out for intensive treatments? Leuk Lymphoma 1995;15:Suppl 1:31-40.
11. Specht L. Prognostic factors in Hodgkin's disease. Cancer Treat Rev 1991;18:21-53.
12. Idem. Prognostic factors in Hodgkin's disease. Semin Radiat Oncol 1996;6:146-61.
13. Proctor SJ, Taylor P, Donnan P, Boys R, Lennard A, Prescott RJ. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Eur J Cancer 1991;27:624-9.
14. Proctor SJ, Taylor P, Mackie MJ, et al. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Leuk Lymphoma 1992;7:Suppl 7:17-20.
15. Proctor SJ, Taylor PR. Classical staging of Hodgkin's disease is inappropriate for selecting patients for clinical trials of intensive therapy: the case for the objective use of prognostic factor information in addition to classical staging. Leukemia 1993;7:1911-4.
16. Straus DJ, Gaynor JJ, Myers J, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 1990;8:1173-86.
17. Gobbi PG, Gobbi PG, Mazza P, Zinzani PL. Multivariate analysis of Hodgkin's disease prognosis: fitness and use of a directly predictive equation. Haematologica 1989;74:29-38.
18. Gobbi PG, Cavalli C, Federico M, et al. Hodgkin's disease prognosis: a directly predictive equation. Lancet 1988;1:675-9.
19. Wagstaff J, Steward W, Jones M, et al. Factors affecting remission and survival in patients with advanced Hodgkin's disease treated with MVPP. Hematol Oncol 1986;4:135-47.
20. Hasenclever D, Schmitz N, Diehl V. Is there a rationale for high-dose chemotherapy as first line treatment of advanced Hodgkin's disease? Leuk Lymphoma 1995;15:Suppl 1:47-9.
21. Fermé C, Bastion Y, Brice P, et al. Prognosis of patients with advanced Hodgkin's disease: evaluation of four prognostic models using 344 patients included in the Group d'Etudes des Lymphomes de l'Adulte Study. Cancer 1997;80:1124-33.
22. Gobbi PG, Comelli M, Grignani GE, Pieresca C, Bertoloni D, Ascari E. Estimate of expected survival at diagnosis in Hodgkin's disease: a means of weighting prognostic factors and a tool for treatment choice and clinical research: a report from the International Database on Hodgkin's Disease (IDHD). Haematologica 1994;79:241-55.
23. Reece DE, Connors JM, Spinelli JJ, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/-cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994;83:1193-9.
24. Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992;10:210-8.
25. Fermé C, Bastion Y, Lepage E, et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol 1995;6:543-9.
26. Pfreundschuh MG, Rueffer U, Lathan B, et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. J Clin Oncol 1994;12:580-6.
27. Assouline D, Adeleine P, Jaubert J, et al. Advanced stages of Hodgkin's disease (HD): long term results of the LMS 80 protocol. Proc Am Soc Clin Oncol 1993;12:381. abstract.
28. Somers R, Carde P, Henry-Amar M, et al. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 1994; 12:279-87.
29. Radford JA, Crowther D, Rohatiner AZ, et al. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease. J Clin Oncol 1995;13:2379-85.
30. Brusamolino E, Lazzarino M, Morra E, et al. Combination chemotherapy with alternating MOPP-ABVD in advanced Hodgkin's disease. Haematologica 1989;74:173-9.
31. Brusamolino E, Orlandi E, Morra E, et al. Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy. Ann Oncol 1994;5:Suppl 2:53-7.
32. Fermé C, Lepage E, Brice P, et al. Combined chemotherapy-radiotherapy in advanced Hodgkin's disease: results of a prospective clinical trial with 70 stage IIIB-IV patients. Int J Radiat Oncol Biol Phys 1993;26:397-405.
33. Fermé C, Brice P, Bourstyn E, et al. Surgical restaging of advanced Hodgkin's disease after first line chemotherapy. Eur J Haematol 1991;46: 306-11.
34. Hill M, Milan S, Cunningham D, et al. Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity. J Clin Oncol 1995;13:387-95.
35. Gobbi PG, Pieresca C, Federico M, et al. MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group. J Clin Oncol 1993;11:712-9.
36. Glick JH, Young ML, Harrington D, et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol 1998;16:19-26.
37. Horning SJ, Ang PT, Hoppe RT, Rosenberg SA. The Stanford experience with combined procarbazine, Alkeran and vinblastine (PAVe) and radiotherapy for locally extensive and advanced stage Hodgkin's disease. Ann Oncol 1992;3:747-54.
38. Horning SJ, Rosenberg SA, Hoppe RT. Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: an update. Ann Oncol 1996;7:Suppl 4:105-8.
39. Specht L, Nissen NI. Prognostic factors in Hodgkin's disease stage III with special reference to tumour burden. Eur J Haematol 1988;41:80-7.
40. Idem. Prognostic factors in Hodgkin's disease stage IV. Eur J Haematol 1988;41:359-67.
41. Hancock BW, Vaughan Hudson G, Vaughan Hudson B, et al. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial. J Clin Oncol 1992;10:1252-8.
42. Hancock BW, Vaughan Hudson G, Vaughan Hudson B, Linch DC, Anderson L, MacLennan KA. Hybrid LOPP/EVA is not better than LOPP alternating with EVAP: a prematurely terminated British National Lymphoma Investigation randomized trial. Ann Oncol 1994;5:Suppl 2: 117-20.
43. Holte H, Mella O, Wist E, Telhaug R, Hannisdal E, Abrahamsen AF. ChlVPP is as effective as alternating ChlVPP/ABOD in advanced stage Hodgkin's disease. Acta Oncol 1996;35:Suppl 8:73-80.
44. Glimelius B, Enblad G, Kalkner M, et al. Treatment of Hodgkin's disease: the Swedish National Care Programme experience. Leuk Lymphoma 1996;21:71-8.
45. Simmonds PD, Mead GM, Sweetenham JW, et al. PACE BOM chemotherapy: a 12-week regimen for advanced Hodgkin's disease. Ann Oncol 1997;8:259-66.
46. Uziely B, Isacson R, Weshler Z, Lugassy G, Libson E, Polliak A. Hodgkin's lymphoma: results of ABVD chemotherapy in 40 patients with advanced or bulky disease. Leuk Lymphoma 1990;1:123-7.
47. Lotan C, Paltiel O, Dann E, Gordon L, Uziely B, Polliak A. MOPP-ABV for advanced Hodgkin's disease: results from Hadassah University Hospital 1990-1993. Ann Oncol 1996;7:Suppl 3:114. abstract.
48. Hopper KD, Diehl LF, Lynch JC, McCauslin MA. Mediastinal bulk in Hodgkin disease: method of measurement versus prognosis. Invest Radiol 1991;26:1101-10.
49. Kaplan HS. Hodgkin's disease. 2nd ed. Cambridge, Mass.: Harvard University Press, 1980.
50. Ranson MR, Radford JA, Swindell R, et al. An analysis of prognostic factors in stage III and IV Hodgkin's disease treated at a single centre with MVPP. Ann Oncol 1991;2:423-9.
51. Munker R, Hasenclever D, Brosteanu O, Hiller E, Diehl V. Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases: German Hodgkin's Lymphoma Study Group. J Clin Oncol 1995;13:403-9.
52. Anderson H, Jenkins JP, Brigg DJ, et al. The prognostic significance of mediastinal bulk in patients with stage IA-IVB Hodgkin's disease: a report from the Manchester Lymphoma Group. Clin Radiol 1985;36:449-54.
53. Gobbi PG, Gendarini A, Crema A, et al. Serum albumin in Hodgkin's disease. Cancer 1985;55:389-93.
54. Gobbi PG, Cavalli C, Gendarini A, et al. Prognostic significance of serum albumin in Hodgkin's disease. Haematologica 1986;71:95-102.
55. MacLennan KA, Vaughan Hudson B, Easterling MJ, Jelliffe AM, Vaughan Hudson G, Haybittle JL. The presentation haemoglobin level in 1103 patients with Hodgkin's disease (BNLI report no. 21). Clin Radiol 1983;34:491-5.
56. Vaughan Hudson B, MacLennan KA, Bennett MH, Easterling MJ, Vaughan Hudson G, Jelliffe AM. Systemic disturbance in Hodgkin's disease and its relation to histopathology and prognosis (BNLI report no. 30). Clin Radiol 1987;38:257-61.
57. Tubiana M, Attie E, Flamant R, Gerard-Marchant R, Hayat M. Prognostic factors in 454 cases of Hodgkin's disease. Cancer Res 1971;31:1801-10.
58. Anderson H, Crowther D, Deakin DP, Ryder WD, Radford JA. A randomised study of adjuvant MVPP chemotherapy after mantle radiotherapy in pathologically staged IA-IIB Hodgkin's disease: 10-year follow-up. Ann Oncol 1991;2:Suppl 2:49-54.
59. Carella AM, Prencipe E, Pungolino E, et al. Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy. Leuk Lymphoma 1996;21:63-70.
60. Federico M, Clo V, Carella AM. High-dose therapy autologous stem cell transplantation vs conventional therapy for patients with advanced Hodgkin's disease responding to first-line therapy: analysis of clinical characteristics of 51 patients enrolled in the HD01 protocol: EBMT/ANZLG/ Intergroup HD01 Trial. Leukemia 1996;10:Suppl 2:69-71.
61. Schmitz N, Hasenclever D, Brosteanu O, et al. Early high-dose therapy to consolidate patients with high-risk Hodgkin's disease in first remission? Results of an EBMT/GHSG matched-pair analysis. Blood 1995;86:Suppl 1:439a. abstract.
62. Lee SM, Radford JA, Ryder WD, Collins CD, Deakin DP, Crowther D. Prognostic factors for disease progression in advanced Hodgkin's disease: an analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapy. Br J Cancer 1997;75:110-5.
63. Pizzolo G, Vinante F, Chilosi M, et al. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage. Br J Haematol 1990;75:282-4.
64. Gause A, Jung W, Schmits R, et al. Soluble CDS, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma. Ann Oncol 1992;3:Suppl 4:49-52.
65. Trumper L, Jung W, Dahl G, Diehl V, Gause A, Pfreundschuh M. Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease. Ann Oncol 1994; 5:Suppl 1:93-6.
66. Gorschülter M, Bohlen H, Hasenclever D, Diehl V, Tesch H. Serum cytokine levels correlate with clinical parameters in Hodgkin's disease. Ann Oncol 1995;6:477-82.